Abstracts tagged "IL-6 and rheumatoid arthritis"

Abstract Number: 3224 • ACR/ARHP Annual Meeting 2016
Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study
Yoshiya Tanaka¹, Daniel Aletaha², Clifton Bingham III³, Prasheen Agarwal⁴, Regina Kurrasch⁵ and Sharon Popik⁴, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, King of Prussia, PA
Background/Purpose: A global, phase 3 study (SIRROUND-T) evaluating the efficacy and safety of sirukumab, a selective, high-affinity human monoclonal antibody to IL-6, has recently been…
Abstract Number: 1529 • ACR/ARHP Annual Meeting 2014
Evaluation of the Pharmacokinetics and Safety of the Interactions Between the Anti-Interleukin-6 Monoclonal Antibody Sirukumab and Cytochrome P450 Activities in Patients with Rheumatoid Arthritis
Dick de Vries, Yanli Zhuang, Stanley Marciniak, Zhenhua Xu, Dion Chen, Hugh M. Davis, Honghui Zhou and Francisco Leon, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: Interleukin 6 (IL-6) reduces the expression of cytochrome P450 (CYP) enzymes. The goal of the study was to evaluate: 1) the effect of sirukumab…